These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35205752)

  • 1. VISTA in Soft Tissue Sarcomas: A Perspective for Immunotherapy?
    Albertsmeier M; Altendorf-Hofmann A; Lindner LH; Issels RD; Kampmann E; Dürr HR; Angele MK; Klauschen F; Werner J; Jungbluth AA; Knösel T
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma.
    Jlassi A; Rejaibi R; Manai M; Sahraoui G; Guerfali FZ; Charfi L; Mezlini A; Manai M; Mrad K; Doghri R
    Front Oncol; 2024; 14():1352053. PubMed ID: 38634058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Testis Antigens and Immunotherapy: Expression of PRAME Is Associated with Prognosis in Soft Tissue Sarcoma.
    Albertsmeier M; Altendorf-Hofmann A; Lindner LH; Issels RD; Kampmann E; Dürr HR; Schubert-Fritschle G; Angele MK; Kirchner T; Jungbluth AA; Knösel T
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS).
    Berclaz LM; Altendorf-Hofmann A; Lindner LH; Burkhard-Meier A; Di Gioia D; Dürr HR; Klein A; Albertsmeier M; Schmidt-Hegemann NS; Klauschen F; Knösel T
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.
    Kitsou M; Ayiomamitis GD; Zaravinos A
    Int J Oncol; 2020 Jul; 57(1):237-248. PubMed ID: 32468013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
    Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
    Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas.
    Kim JR; Moon YJ; Kwon KS; Bae JS; Wagle S; Kim KM; Park HS; Lee H; Moon WS; Chung MJ; Kang MJ; Jang KY
    PLoS One; 2013; 8(12):e82870. PubMed ID: 24349382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
    Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
    Front Immunol; 2020; 11():563044. PubMed ID: 33250890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Assessment of Immune Checkpoint Regulator VISTA on Tumor-Associated Immune Cells and Platelet-to-Lymphocyte Ratio Identifies Advanced Germ Cell Tumors with Higher Risk of Unfavorable Outcomes.
    Pęksa R; Kunc M; Popęda M; Piątek M; Bieńkowski M; Żok J; Starzyńska A; Perdyan A; Sowa M; Duchnowska R; Biernat W
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33916925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High VISTA expression is linked to a potent epithelial-mesenchymal transition and is positively correlated with PD1 in breast cancer.
    Rezouki I; Zohair B; Ssi SA; Karkouri M; Razzouki I; Elkarroumi M; Badou A
    Front Oncol; 2023; 13():1154631. PubMed ID: 37152039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.
    Italiano A; Bellera C; D'Angelo S
    J Hematol Oncol; 2020 May; 13(1):55. PubMed ID: 32430039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.
    Zhang M; Pang HJ; Zhao W; Li YF; Yan LX; Dong ZY; He XF
    BMC Cancer; 2018 May; 18(1):511. PubMed ID: 29720116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
    Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
    Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
    Böger C; Behrens HM; Krüger S; Röcken C
    Oncoimmunology; 2017; 6(4):e1293215. PubMed ID: 28507801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA.
    Hid Cadena R; Reitsema RD; Huitema MG; van Sleen Y; van der Geest KSM; Heeringa P; Boots AMH; Abdulahad WH; Brouwer E
    Front Immunol; 2019; 10():1638. PubMed ID: 31379838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy Resistance in Neoadjuvantly Treated Gastric Cancer and Cancer of the Gastroesophageal Junction is Associated with an Increased Expression of Immune Checkpoint Inhibitors-Comparison Against a Therapy Naïve Cohort.
    Schoop H; Bregenzer A; Halske C; Behrens HM; Krüger S; Egberts JH; Röcken C
    Transl Oncol; 2020 Feb; 13(2):165-176. PubMed ID: 31865179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer.
    Cao X; Ren X; Zhou Y; Mao F; Lin Y; Wu H; Sun Q
    Front Oncol; 2020; 10():583966. PubMed ID: 33505908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
    Ren X; Wu H; Lu J; Zhang Y; Luo Y; Xu Q; Shen S; Liang Z
    Cancer Biol Ther; 2018 May; 19(5):373-380. PubMed ID: 29336717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.